Affimed N.V. (AFMD)
- Previous Close
5.3500 - Open
5.3600 - Bid 4.8000 x 100
- Ask 4.9900 x 100
- Day's Range
4.8650 - 5.4350 - 52 Week Range
2.2400 - 11.1000 - Volume
65,470 - Avg. Volume
93,633 - Market Cap (intraday)
74.31M - Beta (5Y Monthly) 2.09
- PE Ratio (TTM)
-- - EPS (TTM)
-7.5500 - Earnings Date May 21, 2024 - May 27, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
22.47
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.
www.affimed.comRecent News: AFMD
Performance Overview: AFMD
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AFMD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AFMD
Valuation Measures
Market Cap
74.31M
Enterprise Value
17.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.27
Price/Book (mrq)
1.21
Enterprise Value/Revenue
2.09
Enterprise Value/EBITDA
-0.17
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-43.50%
Return on Equity (ttm)
-100.55%
Revenue (ttm)
13.91M
Net Income Avi to Common (ttm)
-105.94M
Diluted EPS (ttm)
-7.5500
Balance Sheet and Cash Flow
Total Cash (mrq)
38.53M
Total Debt/Equity (mrq)
33.47%
Levered Free Cash Flow (ttm)
-105.8M